T Cell News and Research

Latest T Cell News and Research

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.

29 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Scientists show how individual neurons in the human brain react to morphed faces

An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.

29 Sep 2014

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.

29 Sep 2014

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.

29 Sep 2014

Scientists reveal that human brain can trigger random behavior

Many of the choices we make are informed by experiences we've had in the past. But occasionally we're better off abandoning those lessons and exploring a new situation unfettered by past experiences.

29 Sep 2014

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer.

29 Sep 2014

Scientists discover mechanism that resists cancer drugs in estrogen-positive breast cancer

Scientists have discovered a previously unknown mechanism by which estrogen prepares cells to divide, grow and, in the case of estrogen-positive breast cancers, resist cancer drugs. The researchers say the work reveals new targets for breast cancer therapy and will help doctors predict which patients need the most aggressive treatment.

29 Sep 2014

Researchers create new Cas9 animal model for in vivo genome editing experiments

Researchers from the Broad Institute and Massachusetts Institute of Technology have created a new mouse model to simplify application of the CRISPR-Cas9 system for in vivo genome editing experiments.

29 Sep 2014

Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

The transplantation of faecal microbiota from a healthy donor has been shown in recent clinical studies to be a safe and highly effective treatment for recurrent Clostridium difficile (C. difficile) infection and is now recommended in European treatment guidelines.

29 Sep 2014

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

29 Sep 2014

New, high-throughput method can sort 10 billion bacterial cells in 30 minutes

University of Hawaii at Manoa College of Engineering mechanical engineer Yi Zuo has developed a new, high-throughput method for sorting cells capable of separating 10 billion bacterial cells in 30 minutes.

29 Sep 2014

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

29 Sep 2014

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.

29 Sep 2014

Fecal occult blood screening increases diagnosis rate of high-risk polyps by 89%

The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid.

29 Sep 2014

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

29 Sep 2014

EMD Serono declares winners of first Grant for Oncology Innovation

EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced the winners of the first Grant for Oncology Innovation (GOI), who will receive grants totaling $1.3 million.

27 Sep 2014

State highlights: Calif. gov. vetoes bill limiting Medi-Cal estate recovery, signs birth control, inmate bills

In a blow to tens of thousands of low-income Californians newly enrolled in Medi-Cal under a provision in the Affordable Care Act, Gov. Jerry Brown on Thursday vetoed a bill that would have limited the state's seizure of assets from their estates after they die -- a legal wrinkle that most only discovered after they had signed up for the health care plan for the poor (Seipel, 9/25).

27 Sep 2014

UCLA research may lead to novel treatment for PH1

Research by UCLA biochemists may lead to a new treatment - or even a cure - for PH1, a rare and potentially deadly genetic kidney disease that afflicts children. Their findings also may provide important insights into treatments for Parkinson's disease, Alzheimer's disease and other degenerative diseases.

27 Sep 2014

T Cell News and Research

Latest T Cell News and Research

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Scientists show how individual neurons in the human brain react to morphed faces

Aptose joins Beat AML research collaboration

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Scientists reveal that human brain can trigger random behavior

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

Scientists discover mechanism that resists cancer drugs in estrogen-positive breast cancer

Researchers create new Cas9 animal model for in vivo genome editing experiments

Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

New, high-throughput method can sort 10 billion bacterial cells in 30 minutes

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Fecal occult blood screening increases diagnosis rate of high-risk polyps by 89%

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

EMD Serono declares winners of first Grant for Oncology Innovation

State highlights: Calif. gov. vetoes bill limiting Medi-Cal estate recovery, signs birth control, inmate bills

UCLA research may lead to novel treatment for PH1

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in